Press Releases.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
February 24, 2022--Final data and potential for $25m milestone anticipated in H1 2023--
-
January 20, 2022Company remains on track to submit IND and initiate Phase 1 study in second quarter 2022
-
November 24, 2021Definitive Agreement for $34.6 Million in Gross Proceeds
-
November 10, 2021-Company advances RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)-
-
October 12, 2021-Company will advance RGLS8429 supported by strong preclinical data and superior pharmacologic profile as compared to first-generation RGLS4326-
-
August 10, 2021Completed Preparations and Request for FDA Meeting to Obtain Feedback on Approach to Addressing Remaining Hold Requirements
-
August 03, 2021--Company also Announces Participation in a Panel Discussion at the 2021 Wedbush PacGrow Healthcare Conference
-
June 25, 2021Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in the first cohort of patients with ADPKD